Loading…
Kailera Therapeutics, Inc. is projected to decline to $19.61 by 2027, a -11% move from its current price of $21.91.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $21.14 | $21.90 | $22.69 | -0.03% |
| May 30 | $20.83 | $21.90 | $23.02 | -0.06% |
| May 31 | $20.59 | $21.89 | $23.27 | -0.08% |
| Jun 1 | $20.39 | $21.89 | $23.49 | -0.11% |
| Jun 2 | $20.22 | $21.88 | $23.68 | -0.14% |
| Jun 3 | $20.06 | $21.87 | $23.85 | -0.17% |
| Jun 4 | $19.92 | $21.87 | $24.01 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.92 | $21.87 | $24.01 | -0.19% |
| Week 2 | $19.12 | $21.82 | $24.91 | -0.39% |
| Week 3 | $18.53 | $21.78 | $25.61 | -0.58% |
| Week 4 | $18.04 | $21.74 | $26.20 | -0.78% |
| Week 5 | $17.61 | $21.70 | $26.74 | -0.97% |
| Week 6 | $17.23 | $21.65 | $27.22 | -1.16% |
| Week 7 | $16.88 | $21.61 | $27.67 | -1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kailera Therapeutics, Inc. (KLRA) operates as a clinical-stage biopharmaceutical company focused on obesity and related conditions. It develops clinical- and preclinical-stage therapies, with a pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
KLRA is a healthcare stock currently trading around $21.17 per share, with a market capitalization of $2.74B, and it ranks 1795th by market cap.
The current price is $21.17 and the market cap is $2.74B.
The near-term forecast paths show a mixed outlook. The 2026 average price is $21.17 with a 30-day range of $16.64 to $26.94 and 0% ROI, signaling a NEUTRAL near term.
Longer-term forecasts imply bullish upside, with 2030 average price $26.40 and 24.7% ROI, 2040 average $32.97 and 55.7% ROI, and 2050 average $68.43 and 223.2% ROI; the 2050 maximum is $157.38.
A major floor 10.8% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 18.7% above — a clean break opens room to run.
A major ceiling 18.7% above — clearing it would confirm fresh momentum.
Key KLRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.55 | $21.91 | $30.10 | 0% | Neutral | |
| $14.13 | $19.61 | $29.43 | -11% | Neutral | |
| $15.73 | $23.14 | $36.91 | +6% | Neutral | |
| $17.00 | $26.31 | $43.98 | +20% | Bullish | |
| $16.86 | $27.33 | $47.51 | +25% | Bullish | |
| $16.27 | $27.55 | $49.53 | +26% | Bullish | |
| $14.87 | $26.24 | $48.63 | +20% | Neutral | |
| $14.46 | $26.55 | $50.54 | +21% | Bullish | |
| $13.81 | $26.35 | $51.41 | +20% | Bullish | |
| $14.87 | $29.49 | $58.86 | +35% | Bullish | |
| $15.26 | $33.92 | $74.31 | +55% | Bullish | |
| $31.93 | $70.95 | $163.17 | +224% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $19.55 | $21.91 | $25.87 | +0.00% |
| June 2026 | $17.45 | $20.92 | $25.98 | -4.52% |
| July 2026 | $17.52 | $21.36 | $27.20 | +2.10% |
| August 2026 | $17.94 | $22.15 | $28.76 | +3.72% |
| September 2026 | $17.39 | $21.72 | $28.63 | -1.97% |
| October 2026 | $16.94 | $21.37 | $28.57 | -1.59% |
| November 2026 | $17.31 | $22.03 | $29.81 | +3.08% |
| December 2026 | $17.13 | $22.00 | $30.10 | -0.14% |
Click any year to see its month-by-month KLRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KLRA to range from $19.55 to $30.10 through 2026. The $21.91 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KLRA price prediction for 2027 points to an average of $19.61 (low $14.13, high $29.43) — a potential decline of -11% on today's $21.91. Price action looks broadly range-bound.
In 2028, KLRA is projected to trade between $15.73 and $36.91, averaging $23.14 — a potential gain of +6% from today's $21.91. That is up +18% on the projected 2027 average. A consolidation phase looks the most probable path here.
Kailera Therapeutics, Inc.'s 2029 outlook centres on $26.31, within a $17.00 to $43.98 range. That is up +14% on the projected 2028 average. That marks a +20% change versus current levels. Momentum favours further upside here.
By 2030, KLRA could reach as high as $47.51, with a base case around $27.33 and support toward $16.86 — roughly +25% from $21.91. Buyers look set to stay in control over this stretch.
Expect KLRA to range from $16.27 to $49.53 through 2031. The $27.55 average target implies a +26% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The KLRA price prediction for 2032 points to an average of $26.24 (low $14.87, high $48.63) — a potential gain of +20% on today's $21.91. A consolidation phase looks the most probable path here.
In 2033, KLRA is projected to trade between $14.46 and $50.54, averaging $26.55 — a potential gain of +21% from today's $21.91. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Kailera Therapeutics, Inc.'s 2034 outlook centres on $26.35, within a $13.81 to $51.41 range. That is -1% versus the projected 2033 average. That marks a +20% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KLRA could reach as high as $58.86, with a base case around $29.49 and support toward $14.87 — roughly +35% from $21.91. Momentum favours further upside here.
Expect KLRA to range from $15.26 to $74.31 through 2040. The $33.92 average target implies a +55% move from current prices. That is up +15% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KLRA price prediction for 2050 points to an average of $70.95 (low $31.93, high $163.17) — a potential gain of +224% on today's $21.91. Momentum favours further upside here.
Investing $1,000 in KLRA today (≈ 45.64126 KLRA) could be worth
$3,238.03
+$2,238.03 (+224%) by 2050 · US Dollar
Based on the average projected KLRA price of $70.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KLRAwould be worth at today's price.
$1,000 invested in KLRA on Apr 17, 2026 (≈ 38.461538 KLRA) would be worth
$842.69
-$157.31 (-15.7%) today · 0.84× · US Dollar
Based on a KLRA entry price of $26 vs. today's $21.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.07 | $1,091.68 | +9.2% |
| 1 month ago | $23.51 | $931.94 | -6.8% |
| All time ago | $26 | $842.69 | -15.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KLRA forecast.
Our base-case forecast reaches $44.00 around 2050.
Implied market cap at $44.00: $5.7B
The multi-year forecast shows a transition from neutral in the near term to bullish in the longer term. The forecast projects rising average prices and ROIs through 2030, 2040, and 2050, with 2030 at an average price of $26.40 and ROI of 24.7%, 2040 at $32.97 and ROI 55.7%, and 2050 at $68.43 and ROI 223.2%.
In addition, the model assigns bullish sentiment to 2029 and beyond, with a series of higher highs implied by the projected maximums (e.g., 2030 max $46.45, 2050 max $157.38). The 2029-2035 period shows continued upside, while the long-run outcome remains subject to market conditions and is not a guarantee.
Tap a question to reveal the answer.
The forecast shows an average price of $26.40, a min of $16.04, and a max of $46.45, with ROI of 24.7% and sentiment BULLISH.
Near-term outlook is NEUTRAL (2026-2028) with 0% ROI in 2026 and negative ROI in 2027, followed by bullish momentum in 2029 onward. The 2050 max implies upside with an average around $68.43 and ROI 223.2%, but these are forecasts, not guarantees.
The 2050 maximum price is $157.38, which suggests a potential to exceed $100 according to the forecast, though it is not guaranteed.
30-day range is $16.64 to $26.94; support is $19.55 and resistance is $26.00; RSI(14) is 40 and sentiment is NEUTRAL.
Current price is $21.17 and market cap is $2.74B.
Kailera Therapeutics, Inc. Community Discussion
0Share your Kailera Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.